Posted by Michael Wonder on 21 Feb 2023
Biohaven's taldefgrobep alfa receives FDA fast track designation for spinal muscular atrophy
21 February 2023 - Taldefgrobep alfa, a myostatin-targeting biologic investigational agent, in Phase 3 development to increase muscle mass for spinal muscular atrophy patients now granted fast track in addition to previously receiving orphan drug designation in the US.
Biohaven announced today that it received fast track designation from the US FDA for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy.
